Mereo BioPharma Group (MREO) Competitors

Mereo BioPharma Group logo
$0.29 +0.01 (+5.28%)
Closing price 03:58 PM Eastern
Extended Trading
$0.29 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MREO vs. MDWD, BBOT, ANIK, KROS, and IFRX

Should you buy Mereo BioPharma Group stock or one of its competitors? Mereo BioPharma Group's main competitors and comparable companies include MediWound (MDWD), BridgeBio Oncology Therapeutics (BBOT), Anika Therapeutics (ANIK), Keros Therapeutics (KROS), and InflaRx (IFRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Mereo BioPharma Group compare to MediWound?

MediWound (NASDAQ:MDWD) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

In the previous week, MediWound had 21 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 22 mentions for MediWound and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.60 beat MediWound's score of 0.05 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MediWound
2 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
Mereo BioPharma Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Mereo BioPharma Group has a net margin of 0.00% compared to MediWound's net margin of -234.98%. MediWound's return on equity of -61.68% beat Mereo BioPharma Group's return on equity.

Company Net Margins Return on Equity Return on Assets
MediWound-234.98% -61.68% -30.98%
Mereo BioPharma Group N/A -84.62%-71.44%

MediWound has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

MediWound has higher revenue and earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediWound$16.96M10.49-$23.88M-$2.21N/A
Mereo BioPharma Group$500K87.67-$41.88M-$0.04N/A

46.8% of MediWound shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 9.2% of MediWound shares are held by company insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MediWound currently has a consensus price target of $33.00, indicating a potential upside of 141.23%. Mereo BioPharma Group has a consensus price target of $1.67, indicating a potential upside of 507.16%. Given Mereo BioPharma Group's higher possible upside, analysts plainly believe Mereo BioPharma Group is more favorable than MediWound.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MediWound
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Mereo BioPharma Group
2 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.13

Summary

MediWound beats Mereo BioPharma Group on 8 of the 15 factors compared between the two stocks.

How does Mereo BioPharma Group compare to BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, BridgeBio Oncology Therapeutics had 5 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 6 mentions for BridgeBio Oncology Therapeutics and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.60 beat BridgeBio Oncology Therapeutics' score of 0.46 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Oncology Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Mereo BioPharma Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Mereo BioPharma Group has higher revenue and earnings than BridgeBio Oncology Therapeutics. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Oncology TherapeuticsN/AN/A-$134.04M-$2.16N/A
Mereo BioPharma Group$500K87.67-$41.88M-$0.04N/A

BridgeBio Oncology Therapeutics' return on equity of -49.01% beat Mereo BioPharma Group's return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Oncology TherapeuticsN/A -49.01% -43.18%
Mereo BioPharma Group N/A -84.62%-71.44%

BridgeBio Oncology Therapeutics has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

BridgeBio Oncology Therapeutics presently has a consensus target price of $19.33, indicating a potential upside of 896.56%. Mereo BioPharma Group has a consensus target price of $1.67, indicating a potential upside of 507.16%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than Mereo BioPharma Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Oncology Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82
Mereo BioPharma Group
2 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.13

Summary

BridgeBio Oncology Therapeutics beats Mereo BioPharma Group on 8 of the 13 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Anika Therapeutics?

Anika Therapeutics (NASDAQ:ANIK) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Anika Therapeutics has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

In the previous week, Anika Therapeutics had 3 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 4 mentions for Anika Therapeutics and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.60 beat Anika Therapeutics' score of 0.59 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Anika Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Mereo BioPharma Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Anika Therapeutics currently has a consensus price target of $19.00, indicating a potential upside of 47.86%. Mereo BioPharma Group has a consensus price target of $1.67, indicating a potential upside of 507.16%. Given Mereo BioPharma Group's higher possible upside, analysts plainly believe Mereo BioPharma Group is more favorable than Anika Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anika Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Mereo BioPharma Group
2 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.13

Anika Therapeutics has higher revenue and earnings than Mereo BioPharma Group. Anika Therapeutics is trading at a lower price-to-earnings ratio than Mereo BioPharma Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anika Therapeutics$112.82M1.53-$10.88M-$0.13N/A
Mereo BioPharma Group$500K87.67-$41.88M-$0.04N/A

Mereo BioPharma Group has a net margin of 0.00% compared to Anika Therapeutics' net margin of -1.43%. Anika Therapeutics' return on equity of 1.87% beat Mereo BioPharma Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Anika Therapeutics-1.43% 1.87% 1.39%
Mereo BioPharma Group N/A -84.62%-71.44%

91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 12.1% of Anika Therapeutics shares are held by company insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Anika Therapeutics beats Mereo BioPharma Group on 8 of the 15 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Keros Therapeutics?

Mereo BioPharma Group (NASDAQ:MREO) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 6.5% of Mereo BioPharma Group shares are held by insiders. Comparatively, 12.6% of Keros Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Mereo BioPharma Group currently has a consensus target price of $1.67, indicating a potential upside of 507.16%. Keros Therapeutics has a consensus target price of $20.00, indicating a potential upside of 76.83%. Given Mereo BioPharma Group's higher possible upside, equities analysts plainly believe Mereo BioPharma Group is more favorable than Keros Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mereo BioPharma Group
2 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.13
Keros Therapeutics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.57

Keros Therapeutics has higher revenue and earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mereo BioPharma Group$500K87.67-$41.88M-$0.04N/A
Keros Therapeutics$244.06M0.91$87.01M-$2.82N/A

In the previous week, Keros Therapeutics had 6 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 7 mentions for Keros Therapeutics and 1 mentions for Mereo BioPharma Group. Keros Therapeutics' average media sentiment score of 0.63 beat Mereo BioPharma Group's score of 0.60 indicating that Keros Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mereo BioPharma Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Keros Therapeutics
2 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Mereo BioPharma Group has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.85% beat Mereo BioPharma Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Mereo BioPharma GroupN/A -84.62% -71.44%
Keros Therapeutics -256.60%-21.85%-19.83%

Mereo BioPharma Group has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Summary

Keros Therapeutics beats Mereo BioPharma Group on 11 of the 15 factors compared between the two stocks.

How does Mereo BioPharma Group compare to InflaRx?

InflaRx (NASDAQ:IFRX) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

InflaRx currently has a consensus target price of $7.43, suggesting a potential upside of 545.96%. Mereo BioPharma Group has a consensus target price of $1.67, suggesting a potential upside of 507.16%. Given InflaRx's stronger consensus rating and higher possible upside, research analysts plainly believe InflaRx is more favorable than Mereo BioPharma Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InflaRx
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.67
Mereo BioPharma Group
2 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.13

42.4% of InflaRx shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 16.3% of InflaRx shares are held by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, InflaRx and InflaRx both had 1 articles in the media. InflaRx's average media sentiment score of 1.01 beat Mereo BioPharma Group's score of 0.60 indicating that InflaRx is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
InflaRx
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Mereo BioPharma Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

InflaRx has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

Mereo BioPharma Group has higher revenue and earnings than InflaRx. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InflaRx$30K5,649.18-$51.63M-$0.39N/A
Mereo BioPharma Group$500K87.67-$41.88M-$0.04N/A

InflaRx's return on equity of -32.04% beat Mereo BioPharma Group's return on equity.

Company Net Margins Return on Equity Return on Assets
InflaRxN/A -32.04% -27.33%
Mereo BioPharma Group N/A -84.62%-71.44%

Summary

InflaRx beats Mereo BioPharma Group on 10 of the 14 factors compared between the two stocks.

Get Mereo BioPharma Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MREO vs. The Competition

MetricMereo BioPharma GroupBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$46.31M$3.97B$7.59B$11.71B
Dividend YieldN/A3.63%2.47%4.46%
P/E Ratio-7.2524.5933.6329.90
Price / Sales92.9415.678.455.70
Price / CashN/A22.9521.0121.90
Price / Book1.944.174.463.73
Net Income-$41.88M-$24.10M$3.51B$393.84M
7 Day Performance-5.09%-8.21%-6.33%-5.93%
1 Month Performance-3.96%-6.32%-4.73%-7.24%
1 Year Performance-84.01%-6.58%-1.55%-7.43%

Mereo BioPharma Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MREO
Mereo BioPharma Group
1.809 of 5 stars
$0.29
+5.3%
$1.67
+476.7%
-84.5%$46.15M$500KN/A39
MDWD
MediWound
1.7997 of 5 stars
$14.38
+2.1%
$33.00
+129.5%
-25.6%$186.60M$16.96MN/A121
BBOT
BridgeBio Oncology Therapeutics
4.2014 of 5 stars
$2.29
-0.4%
$21.11
+821.9%
N/A$183.51MN/AN/A88
ANIK
Anika Therapeutics
4.1011 of 5 stars
$13.72
-5.9%
$22.00
+60.4%
+33.2%$183.51M$112.82MN/A235
KROS
Keros Therapeutics
3.2563 of 5 stars
$9.19
+0.2%
$21.40
+133.0%
-34.9%$182.12M$244.06MN/A92

Related Companies and Tools


This page (NASDAQ:MREO) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners